Compositions and methods for immunooncology
US-2024417722-A1 · Dec 19, 2024 · US
Methods for increasing efficacy of lipid formulated siRNA
US10053689B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10053689-B2 |
| Application number | US-201514700938-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 30, 2015 |
| Priority date | Jun 15, 2009 |
| Publication date | Aug 21, 2018 |
| Grant date | Aug 21, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that lowers LDL receptor levels.
First claim
Opening claim text (preview).
The invention claimed is: 1. A kit comprising (1) a first effective unit dosage form of a neutral liposomal formulated siRNA targeting a PCSK9 gene; and (2) a second effective unit dosage form of the neutral liposomal formulated siRNA targeting a PCSK9 gene, wherein the first effective unit dosage form is effective to increase LDLR levels in a human, and wherein the second effective unit dosage form is less than the first effective unit dosage form. 2. The kit of claim 1 , wherein the neutral liposomal formulated siRNA is MC3, SNALP or XTC-2 formulated. 3. The kit of claim 1 , wherein the neutral liposomal formulated siRNA comprises ApoE. 4. The kit of claim 1 , wherein the neutral liposomal formulated siRNA is XTC-2 formulated. 5. The kit of claim 1 , wherein the neutral liposomal formulated siRNA targets a PCSK9 gene and comprises a sense strand and an antisense strand and the antisense strand comprises at least 15 contiguous nucleotides of AD-10792 antisense strand. 6. The kit of claim 1 , wherein the neutral liposomal formulated siRNA comprises AD-10792. 7. The kit of claim 1 , wherein the first effective unit dosage form is effective to lower total serum cholesterol levels in a human by at least 15%. 8. The kit of claim 7 , wherein the second effective unit dosage form is effective to maintain the lowered total serum cholesterol levels. 9. The kit of claim 1 , wherein the second effective unit dosage form is at least two fold less than an effective unit dosage form of the neutral liposomal formulated siRNA targeting a PCSK9 gene that would be administered to a subject without the first effective unit dosage form.
Assignees
Inventors
Classifications
Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9 · CPC title
Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases · CPC title
Antihyperlipidemics · CPC title
against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138) · CPC title
Combination therapy · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10053689B2 cover?
- This invention relates to methods for increasing the efficiency of siRNA administrations via pre-administration of an agent that lowers LDL receptor levels.
- Who is the assignee on this patent?
- Arbutus Biopharma Corp
- What technology area does this patent fall under?
- Primary CPC classification C12N15/1135. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Aug 21 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).